<DOC>
	<DOCNO>NCT00546351</DOCNO>
	<brief_summary>SP746 ( NCT00546351 ) multi-center , open-label , follow-on trial . The purpose trial ass safety tolerability long-term exposure lacosamide ( previously refer SPM 927 ) subject painful distal diabetic neuropathy .</brief_summary>
	<brief_title>Study Evaluating Long-term Safety Efficacy Lacosamide Subjects With Painful Distal Diabetic Neuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subjects complete Study SP743 ( NCT00238524 ) SP874 ( NCT00350103 ) , investigator 's opinion , might benefit longterm administration SP746 ( NCT00546351 ) . Exception : subject prematurely discontinue SP743 ( NCT00238524 ) SP874 ( NCT00350103 ) due lack efficacy due intolerability trial medication ( Visit 5but prior enter Maintenance Phase ) may eligible participate SP746 ( NCT00546351 ) , consultation medical monitor Subject clinically relevant ECG abnormality , QTc interval ≥500 m , and/or QTc interval increase ≥60 ms mean predose QTc value Visit 2 SP743 ( NCT00238524 ) SP874 ( NCT00350103 ) Subject aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ≥3 time upper limit normal range ( ULN ) total bilirubin ≥2 time ULN transaminase ( AST and/or ALT ) ≥5 time ULN Subject clinically relevant medical condition , opinion investigator , jeopardize compromise subject 's ability participate trial Subject pregnant nursing female , childbearing potential surgically sterile , 2 year postmenopausal , practice 2 combine method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Lacosamide</keyword>
</DOC>